Methotrexate and Patch Testing: A Retrospective Review. Issue 4 (15th July 2022)

• Record Type: Journal Article
• Authors: Roberson, Forrest; Luis, Camila; Cruzval-O'Reilly, Estefanía; Lugo-Somolinos, Aída
• Is Part Of: Dermatitis. Volume 33:Issue 4(2022)
• Page Start: 264
• Page End: 267
• Publication Date: 2022-07-15
• Subjects: Skin -- Inflammation -- Periodicals; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; Dermatitis, Contact -- Periodicals; Dermatitis, Atopic -- Periodicals; Dermatitis, Occupational -- Periodicals; Drug Eruptions -- Periodicals; 616.51
• DOI: 10.1097/DER.0000000000000852
• Languages: English
• ISSNs: 1710-3568

Abstract

Abstract : Background: Patch testing while taking systemic immunosuppressants is sometimes unavoidable. Methotrexate (MTX) is the immunosuppressant currently considered least likely to negatively impact patch testing. Objective: The aim of the study was to characterize a cohort of patients patch tested while taking MTX. Methods: This is a retrospective review of patients patch tested at the University of North Carolina Dermatology in Chapel Hill, North Carolina, from 2010 to 2019, comparing patch test results of patients taking MTX with those of a control group. Results: An overall 52.8% positivity rate (356/674) was observed. Sixty two of 674 patients were patch tested while taking MTX, with a 46.8% positivity rate (29/62) compared with 53.4% (327/612) in the control group. The control group experienced 975 reactions, including 637 1+ reactions, 291 2+ reactions, and 47 3+ reactions. The MTX group experienced 50 reactions, including thirty-two 1+ reactions, fourteen 2+ reactions, and four 3+ reactions. The difference between the distributions was not statistically significant. Mean weekly MTX dose was 15.6 mg, whereas mean total accumulated dose was 251.6 mg. There was no statistically significant difference between weekly dose and total accumulated dose in patients with positive or negative results. Conclusions: In our cohort, MTX had no discernible effect on patch test results, supporting use during patch testing with minimal false-negative risk.